Bausch Health Third-Quarter 2026 Earnings Conference Call - VALEANT PHARMACEUTICALS INTERNATIONAL

Explicit Guidance:

• 2026 Full-Year Revenue: Raised to $5.525–5.625 billion (midpoint: 8% YoY growth).
• 2026 Full-Year Adjusted EBITDA: Raised to $3.225–3.275 billion (midpoint: 13% YoY growth).
• 2026 Full-Year Adjusted Cash Flow from Operations: Raised to $1.60–1.675 billion (midpoint: 29% YoY growth).
• Q4 2026 Headwinds: Guidance accounts for an 800 bps revenue reduction and 1,400 bps EBITDA reduction due to gross-to-net accrual adjustments for Zanafaxan (Zafaxan) channel inventory in anticipation of the Medicare price change effective January 1, 2027. An additional 300 bps revenue reduction and 500 bps EBITDA reduction are expected from the normalization of Zafaxan and generic inventory levels.
• 2027 Revenue Outlook: Implicit guidance suggests 2027 revenue of approximately $2.7 billion, implying a net impact of $400–500 million year-over-year reduction due to IRA rebate negotiations and price changes.
• Capital Allocation (Debt): Commitment to early redemptions of 2027 notes and up to $100 million in open market repurchases of public debt.
• Capital Allocation (Equity): Initiation of a $50 million share repurchase program to offset dilution from management equity award vesting in 2027.

Business-Segment Outlook:

• Salix: Continued double-digit growth expected; Zafaxan driven by favorable net realized pricing and solid demand (total retail prescriptions excluding Medicaid grew 1.8% in Q3). Q4 outlook impacted by the aforementioned gross-to-net adjustments.
• International:
  • EMEA: On track for 15 consecutive quarters of organic revenue growth; Poland and Hungary cited as high-growth markets.
  • LATAM: Return to growth driven by top 10 products (18% organic growth); Bede Ecta up 28%. Mexico identified as a key platform for future cardiometabolic expansion.
  • Canada: Organic revenue growth of 7% in Q3; promoted products (Realtris, Captrio) delivering double-digit gains.
• Solta Medical:
  • Global Portfolio: Thermage FLX grew 21%; Fraxel FTX grew 52%; Clear + Brilliant Touch grew 49%.
  • Asia-Pacific: China and Taiwan reported 66% and 23% growth respectively. Q4 2026 expected to return to mid-single-digit organic growth as distributor integration benefits normalize (Q4 reported strong growth anticipated despite November sales pause for acquisition).
  • Korea: Consumables growth of 18% indicates continued usage despite saturated equipment installation base.
  • North America: Volume up in Q3; focus on field execution to counter competitor price points and deal terms.
• Diversified Segments: Dermat franchise expected to strengthen via optimized commercial deployment; Zafaxan pricing changes are the primary variable for near-term performance.

Market and Competitive Outlook:

• Pricing: Zafaxan price reduction to Medicare taking effect January 1, 2027 will drive revenue/EBITDA headwinds; net impact of IRA rebate negotiation to be finalized based on September 2024 agreements.
• Competition (China): Softening consumer confidence and entry of local Chinese and Korean competitors in the skin tightening sector may impact growth rates, though management expects these to "flush out" over time.
• Competition (North America): Increased competition in aesthetics with differing price points and deal terms impacting short-term dynamics.
• Channel Dynamics: Channel inventory adjustments required for Zafaxan ahead of the 2027 price change.

Macro / Industry Outlook:

• Regulatory (IRA): Management anticipates the net impact of the Inflation Reduction Act (IRA) rebates and Medicare price negotiation to result in a $400–500 million year-over-year revenue drag in 2027.
• Supply Chain/Logistics: Integration of a full-service distributor in China (completed with no sales recorded in November) expected to boost revenue in December 2026.
• Tariffs: Previous volatility from tariffs on U.S. imported China goods influenced 2025 revenue phasing; 2026 is viewed as a more normalized period.

Strategic Initiatives:

• R&D Pipeline:
  • Phase III Program: Low-stoke sterol for alcohol-associated hepatitis (AAH) is on track for regulatory approval in 2029. Management deems interim analysis unnecessary given confidence in Phase II data and study design.
• Business Development:
  • Focus Areas: Hepatology, gastroenterology, dermatology, and neuroscience.
  • Strategy: Selective M&A to complement existing commercial capabilities and infrastructure, particularly in EMEA (Poland) and Latin America.
• Operational Priorities:
  • Asset Optimization: Maximizing performance across product lifecycles (e.g., Salix) and investing in R&D (Solta).
  • M&A Integration: Full integration of the Chinese distributor to drive future organic growth in the Solta Asia-Pacific segment.
  • Bausch & Lomb: Interim leadership remains committed to maximizing shareholder value; separation of strategic priorities between BHC and B&L remains clear.

Risks and Headwinds to Outlook:

• Regulatory/Price Pressure: $100 million+ gross-to-net accrual impact in Q4 2026 and full-year 2027 impact from Medicare pricing changes and IRA rebates for Zafaxan.
• Legal/Litigation:
  • FDCPA Litigation (Sifacs): No timeline available for D.C. District Court summary judgment or FDA's new framework for "but-for" causation analysis in NORCH2 remand.
• Market Volatility: Softening consumer spending in China and competitive pricing dynamics in North America and Korea could pressure organic growth trajectories.
• Inventory Normalization: Potential for 300 bps revenue and 500 bps EBITDA headwinds in Q4 2026 due to normalization of channel inventory levels.

Management Tone on the Future:

• Confidence Level: High. Management describes 2026 as "shaping up to be another strong year" and cites "consistent execution" and "14 consecutive quarters" of growth as evidence of strategy strength.
• Sentiment: Positive and disciplined. Emphasis on "operational excellence," "profitable revenue growth," and "cash generation" continues.
• Guidance Stance: Aggressive; raised guidance for the second time in 2026, signaling strong belief in the underlying business momentum despite known near-term headwinds.

Miscellaneous:

• Cash Position: $2 billion cash on hand as of Q3 2026; net debt reduced by $521 million in the quarter and > $1 billion year-to-date.
• Segment Milestone: Q3 2026 marked the first time in company history that all segments (Salix, International, Solta, Diversified) grew both revenue and segment profits simultaneously.
• Dividends: No mention of dividend initiation or changes; focus remains on debt reduction and share buybacks.
• Capex/Opex: No specific forward guidance provided for absolute capex or opex, but management cites "operating leverage" and "productivity opportunities" as key drivers of margin expansion.